This brief note highlights a translational advance with implications for mental health practice by showcasing a novel cellular approach to reducing pathological brain plaque, which is linked to cognitive decline. For clinicians across disciplines, the report illustrates how cutting-edge neuroscience strategies may influence future treatment paradigms, including the use of cell-based tools to modulate disease processes. The emphasis on leveraging native brain cells with targeted engineering demonstrates potential shifts in intervention development that could, over time, affect how neurodegenerative conditions are addressed within therapeutic settings.

Article Title: Scientists turn brain cells into Alzheimer’s plaque cleaners

Link to Science Daily Mind-Brain News: https://www dot sciencedaily dot com/releases/2026/03/260311004720 dot htm

#Alzheimer'sResearch #Neurotherapeutics #CellTherapy #BrainHealth #Neuroscience

Scientists turn brain cells into Alzheimer’s plaque cleaners
https://www dot sciencedaily dot com/releases/2026/03/260311004720 dot htm
Scientists have developed a promising new approach to treating Alzheimer’s disease by turning ordinary brain cells into powerful plaque-clearing machines. Instead of requiring frequent antibody infusions like current therapies, the experimental treatment uses genetically engineered astrocytes — abundant support cells in the brain — that are equipped with a CAR “homing device” similar to those used in cancer immunotherapy.
via Mind & Brain News -- ScienceDaily https://www dot sciencedaily dot com/news/mind_brain/
March 11, 2026 at 05:01PM

Copy and paste broken link above into your browser and replace "dot" with "." for link to work.

We have to do it this way to avoid display of copyrighted images.

A groundbreaking discovery is giving new hope to patients with Alzheimer’s and Parkinson’s. Scientists have developed tiny antibodies capable of rapidly targeting harmful protein clumps that drive these neurodegenerative diseases. These protein aggregates, such as beta-amyloid in Alzheimer’s and alpha-synuclein in Parkinson’s, disrupt brain cells and lead to memory loss, tremors, and cognitive decline.

Unlike traditional therapies, these miniature antibodies can penetrate brain tissue more efficiently and clear the toxic proteins faster. Early lab studies show they can neutralise and remove clumps before they cause severe damage, potentially slowing or even preventing disease progression.

This innovation could pave the way for faster, more effective treatments that go straight to the root cause of these devastating conditions. By using these tiny antibodies, researchers hope to develop therapies that are both powerful and precise, offering patients a better quality of life and renewed hope for the future.

While human trials are still needed, this breakthrough marks a significant step toward fighting diseases that have long eluded effective treatment. The combination of speed, precision, and targeted action makes these tiny antibodies one of the most promising advancements in neurodegenerative research.

Neurodegenerative diseases
#Alzheimers #Parkinsons #Neurodegeneration #DementiaResearch #BrainHealth

Therapeutics & biotech
#AntibodyTherapy #Biotech #MedicalBreakthrough #NeuroTherapeutics #PrecisionMedicine

Research & innovation
#Neuroscience #NeuroResearch #CuttingEdgeScience #FutureOfMedicine #TranslationalMedicine

General science & hope
#HealthInnovation #LifeSciences #HopeForCures #MedicalInnovation #ScienceNews

Being somewhere attempting to replicate the NCCR TransCure model (but we're really early in the process) is both exciting and nerve wracking.

I have more thoughts on this paper, but I'm not sure this is the right forum (I did send them to our team's slack channel).

https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cbic.202400397

#Chemistry #ChemiVerse #DrugDiscovery #Neurotherapeutics

Best quote of the symposium re: how to develop drugs for psychiatric & neurological conditions that you can't reproduce in mice (ie: schizophrenia)

"is an iPSC hearing voices?"

*iPSC = induced pluripotent stem cell

#DrugDiscovery #Neurotherapeutics

2/6 for the morning session with brainbow images. Still only one microscopy scale image (guess I'm used to more imaging focused talks when I go to chem bio ones, at something like this I expect every other talk to have one). This has been pretty much all biology and far outside my wheelhouse, but Szu Wang at UCI and Viviana Gradinaru at Caltech both do incredibly cool work (and make it understandable to someone outside their field).

#BrainBow #Neurotherapeutics

Number of talks so far with a brainbow image at a neurotherapeutics symposium: 1/3.

I feel like I should have made a bingo card for various common things. We've also had a microscopy scale figure (actually the same talk).

#Neurotherapeutics #DrugDiscovery

Promo post: If you're interested in potential collaborations with UCI's Institute for Neurotherapeutics there will be a (free) symposium with seminar speakers on the subject and a chance to meet institute faculty and staff (we love a good interdisciplinary project) on October 6, 2023 at UCI.

*I don't know if there will be a live stream/zoom version since this is mostly aimed at people on campus.

https://neurorx.cohs.uci.edu/2023-inaugural-symposium-for-the-center-for-neurotherapeutics/

#Science #Neurotherapeutics #Biology #Neuroscience #ChemicalBiology

2023 Inaugural Symposium for the Center for Neurotherapeutics

Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics

Machado–Joseph disease (MJD) or spinocerebellar ataxia 3 (SCA3) is a rare, inherited, monogenic, neurodegenerative disease, and the most common SCA worldwide. MJD/SCA3 causative mutation is an abnormal expansion of the triplet CAG at exon 10 within the ATXN3 gene. The gene encodes for ataxin-3, which is a deubiquitinating protein that is also involved in transcriptional regulation. In normal conditions, the ataxin-3 protein polyglutamine stretch has between 13 and 49 glutamines. However, in MJD/SCA3 patients, the size of the stretch increases from 55 to 87, contributing to abnormal protein conformation, insolubility, and aggregation. The formation of aggregates, which is a hallmark of MJD/SCA3, compromises different cell pathways, leading to an impairment of cell clearance mechanisms, such as autophagy. MJD/SCA3 patients display several signals and symptoms in which the most prominent is ataxia. Neuropathologically, the regions most affected are the cerebellum and the pons. Currently, there are no disease-modifying therapies, and patients rely only on supportive and symptomatic treatments. Due to these facts, there is a huge research effort to develop therapeutic strategies for this incurable disease. This review aims to bring together current state-of-the-art strategies regarding the autophagy pathway in MJD/SCA3, focusing on evidence for its impairment in the disease context and, importantly, its targeting for the development of pharmacological and gene-based therapies.

MDPI

Announcement I've been sitting on: I'm joining UCI's new Institute for Neurotherapeutics! While Rob Spitale (@[email protected]) is affiliated with the INT he is on leave from the university (hence my job change) and I'll be working for Brian Paegel (@[email protected]) and INT director Al La Spada.

https://news.uci.edu/2022/10/18/uci-launches-center-for-neurotherapeutics-to-facilitate-drug-discovery-and-therapy-delivery/

#UCI #Neurotherapeutics #Chemistry #ChemicalBiology #ChemBio #ChemiVerse #MedChem #MedicinalChemistry #DrugDiscovery #Collaboration #Science

UCI launches Center for Neurotherapeutics to facilitate drug discovery and therapy delivery

UCI has launched a Center for Neurotherapeutics to facilitate drug discovery for neurological diseases. It's led by Dr. Albert LaSpada, Distinguished Professor of pathology, neurology and biological chemistry, as well as associate dean for research development at the UCI School of Medicine; and

UCI News